Entering text into the input field will update the search result below

Spectrum stock rises 7% on positive data of poziotinib in lung cancer study

Mar. 07, 2022 6:39 AM ETSpectrum Pharmaceuticals, Inc. (SPPI)By: Ravikash, SA News Editor

3D illustration of Lungs, medical concept.

yodiyim/iStock via Getty Images

  • Spectrum Pharmaceuticals (NASDAQ:SPPI) said the group 4 of a trial called ZENITH20 met its main goal evaluating poziotinib in certain patients with non-small lung cancer (NSCLC) who had not received prior therapy.
  • The ZENITH20 study consists of

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.